18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 981-987

  Ambrosini, V ^a   Quarta, C ^a   Zinzani, P L ^a   Fini, M ^b   Giavaresi, G ^b   Torricelli, P ^b   Malvi, D ^a   Nanni, C ^a   Grassetto, G ^c   Rubello, Domenico ^c   Fanti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Anaplastic large cell lymphoma; FDG; NOD SCID; Small animal PET; Xenograft

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER DIAGNOSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG UPTAKE; IMMUNE DEFICIENCY; INOCULATION; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCID MOUSE; TISSUE SECTION; TRACHEAL BIOPSY; TUMOR CELL; XENOGRAFT; ANAPLASTIC LARGE CELL LYMPHOMA; ANIMAL; ANIMAL DISEASE; CANCER TRANSPLANTATION; EARLY DIAGNOSIS; HUMAN; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EARLY DIAGNOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS;

EID: 42549153782     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Falini B: Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 114: 741-760, 2001.
2. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G and Pulford K: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96: 3681-3695, 2000.
3. O'Doherty MJ and Hoskin PJ: Positron emission tomography in the management of lymphomas: a summary. Eur J Nucl Med Mol Imaging 30: s128-s130, 2003.
4. Hoskin PJ: PET in lymphoma: what are the oncologist's need. Eur J Nucl Med Mol Imaging 30: s37-s41, 2003.
5. 18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 4: 104-114, 2002.
6. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H and Goldsmith SJ: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43: 1018-1027, 2002.
7. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J and de Groot T: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13: 1356-1363, 2002.
8. 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44: 1225-1231, 2003.
9. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98: 2930-2934, 2001.
10. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW and Price RR: FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 57: 307-315, 2003.
11. Romer W and Schwaiger M: Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging 1: 101-110, 1998.
12. Massoud TF and Gambhir SS: Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17: 545-580, 2003.
13. Blasberg RG: "In vivo" molecular-genetic imaging: multimodality nuclear and optical combinations. Nucl Med Biol 30: 879-888, 2003.
14. Deroose CM, De A, Loening AM, Chow PL, Ray P and Chatziioannou AF: Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48: 295-303, 2007.
15. Blasberg RG and Tjuvajev JG: Molecular-genetic imaging: current and future perspectives. J Clin Invest 111: 1620-1629, 2003.
16. Blasberg RG: Molecular imaging and cancer. Mol Cancer Ther 2: 335-343, 2003.
17. Herschman HR: Micro-PET imaging and small animal models of disease. Curr Opin Immunol 15: 378-384, 2003.
18. Phelps ME: PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41: 661-681, 2000.
19. Ritman EL: Micro-computed tomography-current status and developments. Annu Rev Biomed Eng 6: 185-208, 2004.
20. Gauvain KM, Garbow JR, Song SK, Hirbe AC and Weilbaecher K: MRI detection of early bone metastases in b16 mouse melanoma models. Clin Exp Metastasis 22: 403-411, 2005.
21. Kulbersh BD, Duncan RD, Magnuson JS, Skipper JB, Zinn K and Rosenthal EL: Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg 133: 511-555, 2007.
22. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF and Chow PL: Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463, 2005.
23. Aliaga A, Rousseau JA, Cadorette J, Croteau E, van Lier JE and Lecomte R: A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9: 144-150, 2007.
24. Tian ZG, Longo DL, Funakoshi S, Asai O, Ferris DK and Widmer M: "In vivo" antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 55: 5335-5341, 1995.
25. Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB and McKee KS: "In vitro" and "in vivo" antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7: 2031-2040, 2001.
26. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K and Mathas S: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 106: 1801-1807, 2005.
27. Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C and Hayhoe FG: A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72: 234-240, 1988.
28. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W and Ambrogio C: Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107: 689-697, 2006.
29. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F and Mohammed S: The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 67: 4278-4286, 2007.
30. Hsu FY, Zhao Y, Anderson WF and Johnston PB: Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy "in vitro". Cancer Invest 25: 240-248, 2007.
31. Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K and McKee KS: CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 65: 6950-6956, 2005.
32. Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z and Talanov VS: Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA 104: 8444-8448, 2007.